All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...
Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...
World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...
U.S. stock futures are pointing higher ahead of a closely watched inflation report; JPMorgan Chase shares are moving higher ...
US stocks gave up early gains to end mixed. Investors await key consumer inflation data and the start of earnings season on ...
4d
Asian shares are mixed after gains for oil and gas producers helped offset drops for Nvidia and other Big Tech companies on ...
Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback